News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
283,400 Results
Type
Article (15120)
Company Profile (299)
Press Release (267975)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (80278)
Career Advice (163)
Deals (13468)
Drug Delivery (40)
Drug Development (50833)
Employer Resources (31)
FDA (5908)
Job Trends (5243)
News (145922)
Policy (10162)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (930)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21868)
ALS (127)
Alzheimer's disease (1036)
Antibody-drug conjugate (ADC) (241)
Approvals (6108)
Artificial intelligence (260)
Autoimmune disease (114)
Automation (9)
Bankruptcy (105)
Best Places to Work (4602)
BIOSECURE Act (6)
Biosimilars (101)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (345)
Cancer (3136)
Cardiovascular disease (237)
Career advice (149)
Career pathing (7)
CAR-T (219)
CDC (5)
Cell therapy (565)
Cervical cancer (14)
Clinical research (43807)
Collaboration (1152)
Company closure (2)
Compensation (596)
Complete response letters (39)
COVID-19 (1110)
CRISPR (86)
C-suite (557)
Cystic fibrosis (113)
Data (4343)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1386)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (188)
Drug pricing (49)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31757)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51876)
Executive appointments (622)
FDA (7677)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (983)
Gene editing (182)
Generative AI (21)
Gene therapy (490)
GLP-1 (504)
Government (1163)
Grass and pollen (3)
Guidances (166)
Healthcare (6705)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (40)
Indications (67)
Infectious disease (1215)
Inflammatory bowel disease (158)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7358)
IRA (12)
Job creations (905)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (244)
Leadership (11)
Legal (1431)
Liver cancer (41)
Longevity (11)
Lung cancer (421)
Lymphoma (252)
Machine learning (24)
Management (7)
Manufacturing (377)
MASH (130)
Medical device (2709)
Medtech (2718)
Mergers & acquisitions (6734)
Metabolic disorders (725)
Multiple sclerosis (105)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1961)
Neurotech (1)
NextGen: Class of 2026 (2063)
Non-profit (891)
Now hiring (30)
Obesity (329)
Opinion (127)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (302)
Patient recruitment (331)
Peanut (43)
People (26842)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15487)
Phase 2 (20325)
Phase 3 (12906)
Pipeline (3275)
Policy (90)
Postmarket research (859)
Preclinical (6541)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (653)
Real estate (1467)
Recruiting (12)
Regulatory (9960)
Reports (19)
Research institute (973)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (123)
Series A (184)
Series B (136)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (120)
Sponsored (15)
Startups (2011)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (335)
Venture capital (69)
Weight loss (173)
Women's health (26)
Worklife (2)
Date
Today (46)
Last 7 days (323)
Last 30 days (1172)
Last 365 days (17903)
2026 (1710)
2025 (18152)
2024 (20601)
2023 (22488)
2022 (26896)
2021 (27916)
2020 (23489)
2019 (16347)
2018 (11853)
2017 (13817)
2016 (11962)
2015 (14504)
2014 (10531)
2013 (7580)
2012 (7619)
2011 (7718)
2010 (7492)
Location
Africa (157)
Alabama (65)
Alaska (2)
Arizona (74)
Arkansas (5)
Asia (18342)
Australia (3122)
California (7089)
Canada (1846)
China (775)
Colorado (251)
Connecticut (252)
Delaware (244)
Europe (39386)
Florida (905)
Georgia (211)
Hawaii (2)
Idaho (17)
Illinois (397)
India (35)
Indiana (168)
Iowa (8)
Japan (227)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (738)
Massachusetts (5594)
Michigan (113)
Minnesota (250)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1656)
New Mexico (13)
New York (1765)
North Carolina (830)
North Dakota (6)
Northern California (3482)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1287)
Puerto Rico (9)
Rhode Island (25)
South America (221)
South Carolina (9)
Southern California (2811)
Tennessee (40)
Texas (908)
United States (23429)
Utah (98)
Virginia (136)
Washington D.C. (37)
Washington State (594)
West Virginia (1)
Wisconsin (45)
283,400 Results for "pear therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC
Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
March 19, 2024
·
4 min read
Genetown
Pear Therapeutics Announces Process Exploring Strategic Alternatives
Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value.
March 17, 2023
·
5 min read
Business
Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics
Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics.
January 10, 2023
·
11 min read
Deals
Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process
Pear Therapeutics, Inc. announced that the Company and its wholly owned subsidiary, Pear Therapeutics, Inc. each voluntarily filed for protection under chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code.
April 7, 2023
·
5 min read
Business
Pear Therapeutics Reports Third Quarter 2022 Results
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022.
November 14, 2022
·
13 min read
Genetown
Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference
Pear Therapeutics, Inc. today announced the Company will participate in the 43rd Annual Cowen Healthcare Conference being held March 6-8, 2023 in Boston.
February 27, 2023
·
1 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Genetown
Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference
Pear Therapeutics, Inc. (Nasdaq: PEAR) today announced the company will participate in the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California.
November 1, 2022
·
1 min read
Business
Pear Therapeutics Reports Second Quarter 2022 Results
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022.
August 11, 2022
·
14 min read
Genetown
Pear Therapeutics to Participate in LifeSci Partners HealthTech Symposium
Pear Therapeutics, Inc. today announced the company will participate in the LifeSci Partners HealthTech Symposium on September 20, 2022.
September 13, 2022
·
1 min read
1 of 28,340
Next
